期刊文献+

β受体阻滞剂在慢性心力衰竭中的临床应用 被引量:24

下载PDF
导出
摘要 慢性心力衰竭(chronic heart failure,CHF)是各种心血管疾病发展的严重终末阶段,具有高发病率和高病死率的特点。随着社会人口老龄化的发展,CHF已成为心血管疾病患者发生终点不良事件的主要原因。自20世纪60年代以来,β肾上腺素能受体阻滞剂(β受体阻滞剂)已广泛应用于心血管系统疾病的治疗。β受体阻滞剂在心力衰竭、冠心病、高血压、心肌病、心律失常等心血管疾病的治疗中可发挥重要的作用。β受体阻滞剂是目前CHF治疗中最常用和有效的药物之一,不仅可缓解CHF患者的症状、增加运动耐量、提高生活质量,而且可降低CHF患者的死亡率。本文就β受体阻滞剂在 CHF患者中的临床应用做一综述。
出处 《重庆医学》 CAS CSCD 北大核心 2014年第17期2226-2228,共3页 Chongqing medicine
  • 相关文献

参考文献12

  • 1Cowie MR, Mosterd A,Wood DA, et al. The epidemiolo- gy of heart failure[J].Eur Heart,1997,18(2):208-225.
  • 2Wald DS, Law M, Morris JK, et. Combination therapy versus monotherapy in reducing blood pressure., meta a nalysis on 11 000 participants from 42 trials[J].Am J Med,2009,122(3) :290- 300.
  • 3陈瑾,胡大一,张麟,刘秀兰,吴雅峰,李静.卡维地洛对心脏β_1、β_2和α_1受体自身抗体及心功能的影响[J].中华心血管病杂志,2005,33(6):498-501. 被引量:69
  • 4田颖,祝善俊,王江.神经内分泌拮抗治疗慢性心力衰竭的几个热点问题[J].中华心血管病杂志,2005,33(5):485-488. 被引量:42
  • 5王宏宇,胡大一.冠心病的二级预防策略[J].中国医刊,2003,38(7):61-62. 被引量:20
  • 6李勇,诸骏仁.β受体阻滞剂治疗慢性心力衰竭——COMET研究的意义[J].中华心血管病杂志,2004,32(5):466-468. 被引量:50
  • 7Waagstein F, Bristow MR, Swedberg K, et al. Beneficial Effect metoprolol in idiopathic dilated cardiomyopathy [J]. Lancet,1993,342(12) :1441- 1446.
  • 8Aronow WS. I.eft ventricular diastolic heart failure with normal left ventricular aystolic function in older persons [J].LabClinMed,2001,137(3):316 -323.
  • 9Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadMer- gic effects of chronictrcatment with metoprolol versus carvedilol in the failing heart[J]. Circulation, 1996, 94 (6) :2817-2825.
  • 10Kukin ML, Kahnan J, Cnarney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilolon symptoms, exercise, ejec- tion fraction,and oxidative stress in heart failure[J]. Cir culation, 1999,99(20) :2645-2651.

二级参考文献36

  • 1Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation, 2000, 10:484-486.
  • 2De Mey C. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics-observations with beta-adrenoceptor antagonists. Int J Clin Pharmacol Ther, 1997, 35: 453-457.
  • 3Vanhees L, Aubert A, Fagard R, et al. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol, 1986, 8: 1086-1091.
  • 4De Mey C, Breithaupt-Grogler K, Schloos J, et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol, 1994, 38: 480-483.
  • 5Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J Card Fail, 2003, 9:429-443.
  • 6Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol, 2000, 35: 45-50.
  • 7Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res, 1993, 10:28-34.
  • 8Tang WHW, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol,2002,39:70-78.
  • 9CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandanavian enalapril survival study. N Engl J Med, 1987,316:1429-1435.
  • 10Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996,334:1350-1355.

共引文献169

同被引文献238

引证文献24

二级引证文献327

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部